Tag: Stock
In brief: Sleep rebound, Philips settlement, Invacare noncompliance
September 30, 2022HME News Staff
NEW YORK – HME providers saw a 6.3% decline in their sleep patient volume in the last 12 months, but they expect double-digit growth in the next 12 months, according to the third quarter HME Sleep and Oxygen Survey from Needham.
The decline in sleep is mainly due to a shortage in flow generators. The eventual re-entry of Philips into the flow generator market appears likely to come mostly at the expense of smaller competitors rather than ResMed, according to the survey.
Respondents...
Invacare, Hill-Rom see stock movement
September 13, 2016HME News Staff
ELYRIA, Ohio - Invacare recently lost one investor, but gained two.Linden Advisors sold all of its stake in Invacare during the most recent quarter, according to a disclosure report filed with the Securities and Exchange Commission. It sold 48,554 shares of company stock valued at $604,497. Other hedge funds, including Gotham Asset Management, have sold their stakes in Invacare during the most recent quarter.On the flip side, Alphaone Investment Services bought 54,253 additional shares of Invacare...
Stock movers: Invacare and ResMed
May 12, 2016HME News Staff
Heartland Advisors has picked up 88,747 additional shares of Invacare stock, the firm disclosed in a report filed with the SEC on May 3. Heartland Advisors now holds about 3.6 million shares valued at about $39.95 million. Invacare now makes up about 2.09% of its portfolio…Peter Farrell, a director at ResMed, sold 20,000 shares of the company's stock at an average price of $55.90 in a transaction on May 4 valued at about $1.12 million. He now owns 367,978 shares valued at about $20.6 million.
Stock movers: Ray Huggenberger, Mick Farrell
April 22, 2016HME News Staff
Inogen CEO Ray Huggenberger sold more than half of his shares in the company in a transaction April 15. He sold 29,635 shares at an average price of $48.59 for a total value of $1.44 million. He now owns 25,210 shares…ResMed CEO Mick Farrell sold 5,975 shares at an average price of $59.34 in a transaction on April 15 valued at $354,556. He now owns 154,723 shares.
ResMed's Farrell sells $1M in shares
January 8, 2016HME News Staff
SAN DIEGO - Peter Farrell, founder and chairman of ResMed, sold 20,000 shares of company stock valued at $1.04 million in a transaction on Jan. 4. Farrell still owns 347,978 shares in the company, valued at $18.2 million. On that same day, David Pendarvis, chief administrative officer and global general counsel, sold 6,000 shares valued at $312,960. He still owns 74,287 shares.
Inogen shareholders sell
December 30, 2014HME News Staff
GOLETA, Calif. - Two Inogen shareholders have moved stock this month. Scott Wilkinson sold 15,735 shares on Dec. 29 at an average price of $30.52 per share for a total transaction of $480,232. Versant Ventures sold 9,785 shares on Dec. 23 at an average price of $29.74 for a total transaction of $291,005. Versant Ventures is a majority shareholder in the company, owning at least 10% of its shares.
Inogen exec sells additional shares
September 23, 2014HME News Staff
NEW YORK - Inogen Director Timothy Petersen sold 46,865 shares on Sept. 22 in a transaction worth nearly $1 million. The shares sold at an average price of $21.05 for a total of $986,508. Peterson previously sold 39,135 shares on Sept. 17 in a transaction worth $850,012.
Inogen execs sell shares
September 18, 2014HME News Staff
NEW YORK - Two Inogen executives sold off some of their company stock this week. Vice President Byron Myers sold 22,333 shares Sept. 15 at an average price of $21.33 for a total transaction of $476,362. Director Timothy Peterson sold 39,135 shares Sept. 17 at an average price of $21.72 for a total value of $850,012.
Farrell unloads ResMed stock
May 6, 2014HME News Staff
SAN DIEGO - Peter Farrell, the former CEO of ResMed and a current director, sold 25,000 shares of company stock on the open market in a transaction dated May 1. The stock was sold at $49.80 for a total value of $1.245 million. Farrell still owns 304,990 shares in the company valued at $15.188 million. The sale was disclosed in a document filed with the Securities & Exchange Commission.
INGN opens for trading
February 18, 2014HME News Staff
GOLETA, Calif. - Inogen (INGN) opened for trading on the NASDAQ on Feb. 14, pricing about 4.4 million shares of its stock at $16 per share, the low end of an expected range of $16 to $18. On Feb. 18, the company's stock was trading at $15.28 per share. Inogen filed for an initial public offering (IPO) in November. J.P. Morgan was the sole bookrunner on the deal.